Heparin-Induced Thrombocytopenia Diagnosis and Management

Initial Diagnostic Approach

In ICU patients with thrombocytopenia, immediately calculate the 4T score to assess for heparin-induced thrombocytopenia (HIT), as this is the most critical diagnosis requiring urgent intervention, while simultaneously evaluating for the more common causes including sepsis, hemodilution, consumption, and drug effects 1, 2
Review platelet trend from admission: A >50% drop from baseline, even if count remains >100 × 10³/μL, warrants investigation for HIT 3
Timing is critical: Thrombocytopenia occurring 5-14 days after heparin exposure strongly suggests HIT, while onset <2 days suggests hemodilution or early non-immune heparin effect 4, 3
Earlier onset (<5 days) indicates possible HIT if patient had heparin exposure within the previous 3 months 3

Sepsis and systemic inflammation are the most common causes of thrombocytopenia in ICU patients, associated with disseminated intravascular coagulation (DIC) in severe cases 5
Hemodilution from massive fluid resuscitation causes dilutional thrombocytopenia, particularly post-operatively, and is common after major vascular or cardiac surgery 5, 6
Consumption thrombocytopenia occurs with extracorporeal circuits (ECMO, ventricular assist devices, renal replacement therapy), intra-aortic balloon pumps, and cardiac surgery with cardiopulmonary bypass 5, 3

Stop all heparin exposure immediately and initiate therapeutic-dose alternative anticoagulation immediately, even without thrombosis present, due to high thrombotic risk (30-50% within 30 days) 1, 2
For normal renal and hepatic function, consider argatroban, bivalirudin, fondaparinux, or direct oral anticoagulants (DOACs) as alternative anticoagulants 1, 2, 7
For severe renal impairment (CrCl <30 mL/min), argatroban is the only recommended agent, and for severe hepatic impairment (Child-Pugh C), argatroban is contraindicated 1, 2, 7

Monitor argatroban by targeting aPTT 1.5-3 times baseline, and check aPTT 2 hours after dose initiation or adjustment 1, 2
Danaparoid requires anti-Xa monitoring with specific calibration curve, and use curative IV doses, not prophylactic doses 1, 2

Never use prophylactic doses of alternative anticoagulants—therapeutic doses are mandatory even without documented thrombosis 1, 2, 7
Do not initiate warfarin in acute HIT until platelet count recovers (>150 × 10³/μL), as it can cause venous limb gangrene 7
Do not transfuse platelets in HIT unless life-threatening bleeding, as this may worsen thrombosis 7